Modulation of metastatic potential by cell surface urokinase of murine melanoma cells

Cancer Research

Volumn 48, Issue 5, 1988, Pages 1270-1278

  Hearing, Vincent J ^a   Law, Lloyd W ^a   Corti, Angelo ^b   Appella, Ettore ^a   Blasi, Francesco ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Lepetit Research Laboratories ^*  (Italy)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; CELL CULTURE; CELL SURFACE; CYTOLOGY; MELANOMA CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN;

ANIMAL; ANTIBODIES; FIBRONECTINS; IMMUNOGLOBULINS, FAB; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MOLECULAR WEIGHT; NEOPLASM METASTASIS; PLASMIN; PLASMINOGEN ACTIVATORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0023836852     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Duffy, M. J., and O'Grady, P. Plasminogen activator and cancer. Eur. J. Cancer Clin. Oncol., 20: 577-582, 1984.
2. Mullins, D. E., and Rohrlich, S. T. The role of proteinases in cellular invasiveness. Biochim. Biophys. Acts, 695: 177-214, 1983.
3. Nicolson, G. L. Cancer metastasis: Organ colonization and the cell surface properties of malignant cells. Biochim. Biophys. Acts, 695: 113-176, 1982.
4. Vassalli, J. D., Hamilton, J., and Reich, E. Macrophage plasminogen activatocmodulation of enzyme production by anti-inflammatory steroids, mitotic inhibitors, and cyclic nucleotides. Cell, 8: 271-281, 1976.
5. Strickland, S., Reich, E., and Sherman, M. I. Plasminogen activator in early embryogenesis:enzyme production by trophoblast and parietal endoderm. Cell, 9: 231-240, 1976.
6. Ossowski, L., Biegel, D., and Reich, E. Mammary plasminogen activator: Correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell, 16: 929-940, 1979.
7. Reich, E. Activation of plasminogen. A general mechanism for producing localizedextracellularproteolysis. In. R. D. Berlin et al., eds., Molecular Basis of Biological Degradative Processes, pp. 155-169. New York: Academic Press, 1978.
8. Danø, K., And Reasen, P. A., Grøndahl-Hansen, J., Kristensen, P., Nielson, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
9. Ossowski, L., and Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35: 611-619, 1983.
10. Mignatti, P., Robbins, E., and Rificin, D. B. Tumor invasion through the human amniotic membrane: Requirement for a protein asecascade. Cell, 47: 487-498, 1986.
11. Skriver, L., Larsson, L. I., Kielberg, V., Nielsen, L. S., And Reasen, P. A., Kristensen, P., and Dano, K. Immunocytochemical localization of urokinase type plasmino gen activator in Lewis lung carcinoma. J. Cell Biol., 99: 753-758, 1984.
12. Sullivan, L. M., and Quigley, J. P. An anticatalytic monoclonal antibody to avian plasminogenactivator its effect on behavior of RSV-transformed chick fibroblasts. Cell, 45: 905-915, 1986.
13. Carlsen, S. A., Ramshaw, I. A., and Warrington, R. C. Involvement of plasminogen activator production with tumor metastasis in a rat model. Cancer Res., 44:3012-3016, 1984.
14. Chnstman, J. K., Silagi, S. S., Newcomb, E. W., Acs, G., and Silberstein, S. Correlated suppressionby 5-bromo-deoxyuridine of tumorigenicity and plasminogenactivatorin mousemelanomacells. Proc. Natl. Acad. Sci. USA, 72: 47-50, 1975.
15. Liotta, L. A., Tryggvason, S., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. Metastaticpropensitycorrelateswith tumorcell degradation of basement membrane collagen. Nature (Lond.), 284: 67-68, 1980.
16. Liotta, L. A., Tryggvason, K., Garbisa, S., Robey, P. G., and Abe, S. Partial purification and characterization of a neutral protean which cleavestype IV collagen. Biochemistry, 20: 100-104, 1981.
17. Ossowski, L., Unkeless, J. C., Tobia, A., Quigley, J. P., Rifldn, D. B., and Reich, E. An enzymatic function associated with transformation of fibroblasts by oncogenicviruses. J. Exp. Med., 137: 112-126, 1973.
18. Sisskin, E. E., Weinstein, I. B., Evans, C. H., and Dipaolo, J. A. Plasminogen activator synthesis accompanying chemical carcinogen-induced in vitrotrans formation of Syrian hamster and guinea-pig fetal cells. Int. J. Cancer, 26: 331-335, 1980.
19. Sloane, B. F., Honn, K. V., Sadler, J. G., Turner, W. A., Kimpson, J. J., and Taylor, J. D. Cathepsin B activity in B16 melanoma cells: A possiblemarker for metastaticpotential. Cancer Res., 42:980-986, 1982.
20. Unkeless, J. C., Tobia, A., Ossowski, L., Quigley, J. P., Rilkin, D. B., and Reich, E. An enzymatic function associated with transformation of fibroblasts by oncogenicviruses. I. Chick embryo fibroblast cultures transformed by avian RNA viruses. J. Exp. Med., 137: 85-111, 1973.
21. Chapman, H. A., Jr., Vavrin, Z., and Hibb S. J. B., Jr. Macrophagefibrinolytic activity: Identification of two pathways of plasmin formation by intact cells and of a plasminogenactivator inhibitor. Cell, 28: 653-662, 1982.
22. Jaken, S., and Black, P. H. Correlation betweena specific molecular weight form of plasminogenactivator and metaboliclabeling of 3T3 cells. J. Cell Biol., 90:721-726, 1981.
23. Lemaire, G., Drapier, J. C., and Petit, J. F. Importance, localization and functional properties of the cell-associated form of plasminogen activator in mouse peritonealmacrophages. Biochim. Biophys. Acta, 755:332-343, 1983.
24. Quigley, J. P. Association of a protease(plasminogenactivator) with a specific membrane fraction isolated from transformed cells. J. Cell Biol., 71: 472-486, 1976.
25. Quigley, J. P., Goldfarb, R. H., Schemer, C., O'Donnell-Tormey, J., and Yeo, T. K. Plasminogen activator and the membrane of transformed cells. Prog. Clin. Biol. Res., 41: 773-796, 1980.
26. Solomon, J. A., Chou, I. N., Schroeder, E. W., and Black, P. H. Evidence for membraneassociation of plasminogenactivatoractivity in mousemac rophages. Biochem. Biophys. Res. Commun., 94: 480-486, 1980.
27. Zisapel, N., Miskin, R., Laudon, M., and Soreq, H. Plasminogen activator is enriched in the synaptosomal plasma membranes. Brain Res., 248: 129-139, 1982.
28. Stoppelli, M. P., Corti, A., Soffientini, A., Cassani, G., Blasi, F., and Assoian, R. K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinaseplasminogenactivator to a specific receptor on U937 monocytes. Proc. NatI. Acad. Sci. USA, 82: 4939-4943, 1985.
29. Vassalli, J. D., Baccino, D., and Belin, D. A cellular binding site for the M., 55, 000 form of the human plasminogen activator, urokinase. J. Cell Biol., 100:86-92, 1985.
30. Appella, E., Robinson, E. A., Ullrich, S. J., Stoppelli, M. P., Corti, A., Cassani, G., and Blasi, F. The receptor-binding sequence of urokinase. J. Biol. Chem., 262: 4437-4440, 1987.
31. Stoppelli, M. P., Tacchetti, C., Cubellis, M. V., Corti, A., Hearing, V. J., Cassani, G., Appella, E., and Blasi, F. Autocnne saturation of pro-urokinase receptorson human A431 cells. Cell, 45: 675-684, 1986.
32. Fidler, I. J. Selection of successive tumour lines for metastasis. Nature (Lond.), 242:148-149, 1973.
33. Poste, G., Tzeng, J., Doll, J., Greig, R., Rieman, D., and Zeidman, I. Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc. Natl. Acad. Sd. USA, 79:6574-6578, 1982.
34. Hearing, V. J., Vieira, W. D., and Law, L. W. Malignant melanoma-cross reacting (common) tumor rejection antigens. Int. J. Cancer, 35: 403-409, 1985.
35. Salerno, G., Verde, P., Nolli, M. L., Corti, A., Sorts, H., Meo, T., Johnson, J., Bullock, S., Cassani, G., and Blasi, F. Monoclonal antibodies to human urokinase identify the single-chainpro-urokinase precursor. Proc. Natl. Acad. Sci. USA, 81: 110-114, 1984.
36. Nolli, M. L., Corti, A., Soffientini, A., and Cassani, G. A monoclonal antibody that recognizes the receptor-binding region of human urokinase plasminogen activator. Thromb. Haemo., 56: 214-218, 1987.
37. Ferraiuolo, R., Stoppelli, M. P., Verde, P., Bullock, S., Lazzano, P., Blasi, F., and Pietropaolo, C. T. Transcriptional induction of urokinase in cultured human kidney carcinomacells by tetradecanoyl-phorbol-acetate. J. Cell Physiol., 121:368-374, 1984.
38. Mage, M., and Lamoyi, E. Preparation of F(ab) and F(ab), fragments from monoclonal antibodies. In: Monoclonal Antibodies and Hybridomas. New York: Marcel Dekker, 1987, in press.
39. Porter, R. R. The hydrolysis of rabbit @-globalin and antibodies with crystal line papain. Biochem. J., 73: 119-126, 1959.
40. Hirabsyashi, Y., Hamaoka, A., Matsumoto, M., Matsubara, T., Tagawa, M., Wakabayashi, S., and Taniguchi, M. Syngeneicmonoclonal antibody against melanomaantigen with interspecies cross-reactivity recognizesGM3, a prominent ganglioside of B16 melanoma. J. Biol. Chem., 260: 13328-13333, 1985.
41. Taniguchi, M., and Wakabayashi, S. Monoclonal antitumor antibodies-its applicationto diagnosis and treatment of tumors. Gan No Rinsho, 29: 654-658, 1983.
42. Dippold, W. G., Jay, G., DeLeo, A. B., Khoury, G., and Old, L. J. p53 Transformation related protein:detectionby monoclonalantibodyin mouse and humancells. Proc. Natl. Acad. Sci. USA, 78: 1695-1699, 1981.
43. Tomita, Y., Montague, P. M., and Hearing, V. J. Monoclonal antibody production to a B16 melanoma associated antigen. Int. J. Cancer, 35: 543-547, 1985.
44. Tomita, Y., Montague, P. M., and Hearing, V. J. Anti-tyrosinase monoclonal antibodies-specific markers for melanocytes. J. Invest. Derm., 85: 426-430, 1985.
45. Hubbard, A. L., and Cohn, Z. A. Externally disposedplasma membrane proteins. Enzymaticiodination Of mouseL-cells. J. Cell Biol., 64: 438-460, 1975.
46. Stump, D. C., Thienpont, M., and Cohen, D. Urokinase-related proteins in humanurine. Isolation And characterization of single-chainurokinase(prourokinase) and urokinase-inhibitor complex. J. Biol. Chem., 261: 1267-1273, 1986.
47. Grimaldi, G., DiFiore, P. P., Kajtaniak, E. L., Falco, J., and Blasi, F. Modulation of urokinase plasminogen activator geneexpression during the transition from quiescent to proliferative state in normal mouse cells. Eur. Mol. Biol. Organ. J., 5: 855-861, 1986.
48. Nielsen, L. S., Hansen, J. G., Skriver, L., Wilson, E., Kaltoft, K., and Danø, K. Purification of zymogen to plasminogen activator from human glioblas tomacells by affinity chromatographywith monoclonalantibody. Biochemistry, 21: 6410-6415, 1982.
49. Wun, T., Ossowski, L., and Reich, E. A proenzyme form of human urokinase. J. Biol. Chem., 257: 7262-7266, 1982.
50. Vassalli, J. D., Hamilton, J., and Reich, E. Macrophage plasminogen activator inductionby concanavalinA and phorbolmyristateacetate. Cell, 11: 695-705, 1977.
51. Hearing, V. J., Gersten, D. M., Montague, P. M., Vieira, W. D., Galeno, G., and Law, L. W. Murine melanoma-specific tumor rejection activity elicited by a purified, melanoma-associated antigen. J. Immunol., 137:379-384, 1986.
52. Blasi, F., Vassalli, J. D., and Danø, K. Urokinase-type plasminogen activator: Proenzyme, receptor, and inhibitors. J. Cell Biol., 104: 801-804, 1987.
53. Cubellis, M. V., Nolli, M. L., Cassanni, G., and Blasi, F. Binding of single chain prourokinase to the urokinase receptor of human U937 cells. J. Biol. Chem., 261:15819-15822, 1986.
54. Edwards, P. A. W. Heterogenous expression of cell-surface antigens in normalepithelia and their tumours, revealedby monoclonalantibodies. Br. J. Cancer, 51: 149-160, 1985.
55. Hill, R. P., Chambers, A. F., Ling, V., and Harris, J. F. Dynamic heterogeneity: Rapid generation of metastatic variants in mouseB16 melanoma cells. Science (Wash. DC), 224: 998-1001, 1984.
56. Leong, S. P. L., Noguchi, P. D., Cunningham, R. E., Ames, R. S., Speiss, P. J., Takami, T., and Roth, J. A. Factors governing expression of a murine melanoma-associated membrane antigen analyzedby flow cytometry. J. Surg. Res., 38:383-394, 1985.
57. Richer, M., and Richer, M. S. Metastatic potential correlateswith cell-surface protein alterations in B16 melanoma variants. Nature (Lond.), 293: 74-76, 1981.
58. Yogeeswaran, G., and Salk, P. L. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science (Wash. DC), 212:1514-1516, 1981.
59. Needham, G. K., Sherbert, G. V., Farndon, J. R., and Harris, A. L., Binding of urokinaseto specific receptorsites on human breast cancer membranes. Br. J. Cancer, 55:13-16, 1987.
60. Vollmers, H. P., and Birchmeier, W. Monoclonal antibodies inhibit the adhesion of mouse B16 melanomacellsin vitro and block lung metastasis in vivo. Proc. Natl. Acad. Sci. USA, 80: 3729-3733, 1983.
61. Stump, D. C., Lijnen, H. R., and Collen, D. Purification and characterization of single-chain urokinase-type plasminogen activator from human cell caltures. J. Biol. Chem., 261: 1274-1278, 1986.
62. Humphries, M. J., Olden, K., and Yamada, K. M. A synthetic peptide from fibronect in inhibits experimental metastasis of murinemelanoma cells. Science (Wash. DC), 233: 467-470, 1986.
63. Salonen, E. M., Saksela, O., Vartio, T., Vaheri, A., Nielsen, L. S., and Zeuthen, J. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J. Biol. Chem., 260: 12302-12307, 1985.
64. Terranova, V. P., Williams, J. E., Liotta, L. A., and Martin, G. R. Modulation of the metastatic potential of melanoma cells by laminin and fibronectin. Science (Wash. DC), 226: 982-985, 1984.
65. Liotta, L. A., Goldfarb, R. H., Brundage, R., Siegal, G. P., Terranova, V., and Garbisa, S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and coflagenouscomponents of basement membrane. Cancer Res., 41: 4629-4636, 1981.
66. Liotta, L. A., Guirguis, R., and Stracke, M. Biology of melanoma invasion and metastasis. PigmentCell Res., 1: 5-15, 1987.